Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Toho to Acquire Ishin Pharma, Bring Allostem Distribution In-House
Major drug wholesaler group Toho Holdings said on July 1 that it will acquire regenerative medicine startup Ishin Pharma for an undisclosed sum, making it a subsidiary. The move comes after Ishin won approval for Allostem (nivadstrocel) earlier this year.…
To read the full story
Related Article
- Ishin Eyes Domestic Production of Allostem by August 2028
July 28, 2026
- Chuikyo OKs NHI Listing for Ferring’s Adstiladrin, Ishin’s Allostem Sheet
July 9, 2026
- Chuikyo Clears NHI Listing for Amchepry, Akuugo, and Zolgensma Intrathecal
May 14, 2026
- Chuikyo Sets Reimbursement Pathways for Five Regenerative Medicine Products
April 9, 2026
- Japan OKs Zolgensma Intrathecal Form, Breyanzi Expansion, New EB Therapy
April 6, 2026
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…